AN OPEN-LABEL, SINGLE-DOSE, PHASE 1 STUDY OF THE PHARMACOKINETICS AND SAFETY OF JZP-110 IN SUBJECTS WITH NORMAL OR IMPAIRED RENAL FUNCTION AND WITH END-STAGE RENAL DISEASE REQUIRING HEMODIALYSIS

被引：2
|
作者：
Zomorodi, K. [1 ]
Chen, D. [1 ]
Lee, L. [1 ]
Lasseter, K. [2 ]
Marbury, T. [3 ]
机构：
[1] Jazz Pharmaceut, Palo Alto, CA USA
[2] Clin Pharmacol Miami Inc, Miami, FL USA
[3] Orlando Clin Res Ctr, Orlano, FL USA
来源：
SLEEP | 2017年 / 40卷
关键词：
D O I：
10.1093/sleepj/zsx050.1026
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1027
引用
收藏
页码：A382 / A382
页数：1
相关论文
共 50 条
  • [1] Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis
    Zomorodi, Katie
    Chen, Dan
    Lee, Lawrence
    Lasseter, Kenneth
    Marbury, Thomas
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1120 - 1129
  • [2] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Yalcin Solak
    Seyyid Bilal Acikgoz
    Mehmet Yildirim
    [J]. Clinical Drug Investigation, 2015, 35 : 149 - 149
  • [3] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Suman Wason
    David Mount
    Robert Faulkner
    [J]. Clinical Drug Investigation, 2014, 34 : 845 - 855
  • [4] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Solak, Yalcin
    Acikgoz, Seyyid Bilal
    Yildirim, Mehmet
    [J]. CLINICAL DRUG INVESTIGATION, 2015, 35 (02) : 149 - 149
  • [5] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Wason, Suman
    Mount, David
    Faulkner, Robert
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (12) : 845 - 855
  • [6] Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study
    Dahlke, Marion
    Halabi, Atef
    Canadi, Jasna
    Tsubouchi, Chiaki
    Machineni, Surendra
    Pang, Yinuo
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04): : 474 - 483
  • [7] A Phase 1, Open-Label Evaluation of the Pharmacokinetics And Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function
    Greig, Gerard
    Cong, Danni
    Hurley, Niamh
    Michel, Eric
    Youssef, Nader
    [J]. TRANSPLANTATION, 2022, 106 (09) : S544 - S544
  • [8] A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
    Ermer, James
    Corcoran, Mary
    Lasseter, Kenneth
    Marbury, Thomas
    Yan, Brian
    Martin, Patrick T.
    [J]. THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 546 - 555
  • [9] An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis
    Sunzel, Maria
    Learoyd, Maria
    Li, Jianguo
    Li, Yan
    Ngo, Ngoc
    Edeki, Timi
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (06) : 682 - 688
  • [10] Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study
    Wolzt, M
    Fabrizii, V
    Dorner, GT
    Zanaschka, G
    Leufkens, P
    Krauwinkel, WJJ
    Eichler, HG
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 367 - 373
12345